See more : Julius Bär Gruppe AG (JBARF) Income Statement Analysis – Financial Results
Complete financial analysis of GeNeuro SA (GNRO.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GeNeuro SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Ergomed plc (ERGO.L) Income Statement Analysis – Financial Results
- TAG Immobilien AG (TAGOF) Income Statement Analysis – Financial Results
- Denkyo Group Holdings Co.,Ltd. (8144.T) Income Statement Analysis – Financial Results
- learnd SE (LRND.DE) Income Statement Analysis – Financial Results
- Britania Public Company Limited (BRI.BK) Income Statement Analysis – Financial Results
GeNeuro SA (GNRO.PA)
About GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.46K | 14.95K | 5.92K | 2.54K | 7.31M | 21.10K |
| Cost of Revenue | 293.80K | 288.50K | 300.20K | 334.60K | 354.80K | 70.90K | 72.40K | 43.10K | 31.80K | 0.00 | 0.00 |
| Gross Profit | -293.80K | -288.50K | -300.20K | -334.60K | -354.80K | -63.44K | -57.45K | -37.18K | -29.26K | 7.31M | 21.10K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -850.01% | -384.35% | -628.35% | -1,152.31% | 100.00% | 100.00% |
| Research & Development | 12.31M | 9.68M | 4.72M | 4.54M | 5.98M | 12.85K | 17.52K | 14.94K | 5.62K | 3.64M | 2.65M |
| General & Administrative | 2.97M | 3.17K | 2.59K | 3.23K | 3.70K | 4.51K | 4.36K | 3.55K | 1.83K | 1.00M | 280.40K |
| Selling & Marketing | 82.70K | 3.08M | 2.49M | 3.13M | 3.56M | 407.60 | 494.10 | 275.60 | 131.10 | 0.00 | 0.00 |
| SG&A | 3.05M | 3.08M | 2.49M | 3.13M | 3.56M | 4.92K | 4.85K | 3.83K | 1.97K | 1.00M | 280.40K |
| Other Expenses | -1.19M | -12.70K | -23.80K | -38.20K | -26.50K | -34.40K | -52.00K | -77.40K | -27.40K | 0.00 | 0.00 |
| Operating Expenses | 14.36M | 12.77M | 7.24M | 7.71M | 9.56M | 15.81K | 20.75K | 20.03K | 7.05K | 5.10M | 3.37M |
| Cost & Expenses | 14.36M | 13.06M | 7.54M | 8.04M | 9.92M | 15.81K | 20.75K | 20.03K | 7.05K | 5.10M | 3.37M |
| Interest Income | 0.00 | 7.60 | 1.90 | 72.30 | 441.90 | 21.30 | 34.70 | 9.70 | 46.20 | 14.90K | 34.20K |
| Interest Expense | 952.60K | 269.30K | 40.60K | 80.20K | 448.50K | 31.00K | 35.10K | 7.10K | 6.80K | 8.80K | 113.10K |
| Depreciation & Amortization | 39.60K | 288.50K | 300.20K | 334.60K | 354.80K | 70.90K | 72.40K | 43.10K | 28.90 | 43.60K | 65.10K |
| EBITDA | -14.32M | -11.78M | -6.79M | -9.10M | -9.57M | -8.03M | -5.68M | -12.20M | -4.29M | 2.24M | -3.29M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -107.64% | -38.00% | -206.13% | -169.09% | 31.07% | -15,839.81% |
| Operating Income | -14.36M | -13.06M | -7.54M | -8.04M | -9.92M | -8.09K | -5.74K | -12.24K | -4.32K | 2.20M | -3.35M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -108.38% | -38.40% | -206.77% | -170.23% | 30.13% | -15,882.46% |
| Total Other Income/Expenses | -951.40K | -459.10K | -1.46M | -2.06M | -1.38M | -239.20K | -1.46M | -61.00K | -141.00K | 25.20K | -169.20K |
| Income Before Tax | -15.31M | -13.51M | -7.82M | -9.52M | -10.37M | -8.33K | -5.84K | -14.10K | -4.46K | 2.23M | -3.52M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -111.59% | -39.05% | -238.24% | -175.78% | 30.47% | -16,684.36% |
| Income Tax Expense | -551.70K | -1.31M | -1.01M | -553.90K | -912.40K | -1.92M | -1.36M | 5.50 | 23.50 | 449.80K | -21.60K |
| Net Income | -14.76M | -12.20M | -6.82M | -8.96M | -9.46M | -8.33K | -5.84K | -14.10K | -4.49K | 1.78M | -3.50M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -111.59% | -39.05% | -238.33% | -176.71% | 24.32% | -16,581.99% |
| EPS | -0.59 | -0.51 | -0.32 | -0.45 | -0.65 | -0.57 | -0.40 | -1.02 | -0.37 | 0.15 | -0.29 |
| EPS Diluted | -0.59 | -0.51 | -0.32 | -0.45 | -0.65 | -0.57 | -0.40 | -1.02 | -0.37 | 0.15 | -0.29 |
| Weighted Avg Shares Out | 24.84M | 23.90M | 21.28M | 19.97M | 14.56M | 14.58K | 14.59K | 13.83K | 12.05K | 12.05M | 12.05M |
| Weighted Avg Shares Out (Dil) | 24.84M | 23.90M | 21.28M | 19.97M | 14.56M | 14.58K | 14.59K | 13.87K | 12.17K | 12.05M | 12.05M |
Source: https://incomestatements.info
Category: Stock Reports